Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter.

Kawamura E, Yamada Y, Harashima H.

Mitochondrion. 2013 Nov;13(6):610-4. doi: 10.1016/j.mito.2013.08.010. Epub 2013 Sep 4.

PMID:
24012978
2.

Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter.

Yamada Y, Harashima H.

Biomaterials. 2012 Feb;33(5):1589-95. doi: 10.1016/j.biomaterials.2011.10.082. Epub 2011 Nov 21.

PMID:
22105068
3.
4.

Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.

Yamada Y, Furukawa R, Yasuzaki Y, Harashima H.

Mol Ther. 2011 Aug;19(8):1449-56. doi: 10.1038/mt.2011.99. Epub 2011 Jun 21.

5.

Targeting the mitochondrial genome via a dual function MITO-Porter: evaluation of mtDNA levels and mitochondrial function.

Yamada Y, Harashima H.

Methods Mol Biol. 2015;1265:123-33. doi: 10.1007/978-1-4939-2288-8_10.

PMID:
25634272
6.

Mitochondrial delivery of bongkrekic acid using a MITO-Porter prevents the induction of apoptosis in human HeLa cells.

Yamada Y, Nakamura K, Furukawa R, Kawamura E, Moriwaki T, Matsumoto K, Okuda K, Shindo M, Harashima H.

J Pharm Sci. 2013 Mar;102(3):1008-15. doi: 10.1002/jps.23442. Epub 2013 Jan 11.

PMID:
23315986
7.

[Targeting mitochondria: innovation from mitochondrial drug delivery system (DDS) to mitochondrial medicine].

Yamada Y, Harashima H.

Yakugaku Zasshi. 2012;132(10):1111-8. Review. Japanese.

8.

Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide.

Kawamura E, Yamada Y, Yasuzaki Y, Hyodo M, Harashima H.

J Biosci Bioeng. 2013 Nov;116(5):634-7. doi: 10.1016/j.jbiosc.2013.05.001. Epub 2013 Jun 2.

PMID:
23735326
9.

Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity.

Yamada Y, Munechika R, Kawamura E, Sakurai Y, Sato Y, Harashima H.

J Pharm Sci. 2017 Sep;106(9):2428-2437. doi: 10.1016/j.xphs.2017.04.058. Epub 2017 May 3.

PMID:
28478130
10.

Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.

Yasuzaki Y, Yamada Y, Harashima H.

Biochem Biophys Res Commun. 2010 Jun 25;397(2):181-6. doi: 10.1016/j.bbrc.2010.05.070. Epub 2010 May 16.

PMID:
20580633
11.

Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier.

Yamada Y, Harashima H.

Mitochondrion. 2013 Sep;13(5):526-32. doi: 10.1016/j.mito.2012.09.001. Epub 2012 Sep 19.

PMID:
23000575
12.

MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis.

Yamada Y, Harashima H.

Handb Exp Pharmacol. 2017;240:457-472. doi: 10.1007/164_2016_4. Review.

PMID:
27830347
13.

Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver.

Yamada Y, Nakamura K, Abe J, Hyodo M, Haga S, Ozaki M, Harashima H.

J Control Release. 2015 Sep 10;213:86-95. doi: 10.1016/j.jconrel.2015.06.037. Epub 2015 Jul 6.

PMID:
26160304
14.

A Dual-Ligand Liposomal System Composed of a Cell-Penetrating Peptide and a Mitochondrial RNA Aptamer Synergistically Facilitates Cellular Uptake and Mitochondrial Targeting.

Yamada Y, Furukawa R, Harashima H.

J Pharm Sci. 2016 May;105(5):1705-1713. doi: 10.1016/j.xphs.2016.03.002. Epub 2016 Apr 5.

PMID:
27056631
15.

Validation of a Strategy for Cancer Therapy: Delivering Aminoglycoside Drugs to Mitochondria in HeLa Cells.

Abe J, Yamada Y, Harashima H.

J Pharm Sci. 2016 Feb;105(2):734-740. doi: 10.1002/jps.24686. Epub 2016 Jan 29.

PMID:
26523487
16.

MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion.

Yamada Y, Akita H, Kamiya H, Kogure K, Yamamoto T, Shinohara Y, Yamashita K, Kobayashi H, Kikuchi H, Harashima H.

Biochim Biophys Acta. 2008 Feb;1778(2):423-32. Epub 2007 Nov 12.

17.

A method for screening mitochondrial fusogenic envelopes for use in mitochondrial drug delivery.

Yamada Y, Harashima H.

Methods Mol Biol. 2014;1141:57-66. doi: 10.1007/978-1-4939-0363-4_2.

PMID:
24567130
18.

[MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].

Furukawa R, Yamada Y, Harashima H.

Yakugaku Zasshi. 2012;132(12):1389-98. Review. Japanese.

19.

Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.

Furukawa R, Yamada Y, Kawamura E, Harashima H.

Biomaterials. 2015 Jul;57:107-15. doi: 10.1016/j.biomaterials.2015.04.022. Epub 2015 Apr 24.

PMID:
25913255
20.

An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles.

Yamada Y, Fukuda Y, Harashima H.

Mitochondrion. 2015 Sep;24:50-5. doi: 10.1016/j.mito.2015.07.003. Epub 2015 Jul 15.

PMID:
26188112

Supplemental Content

Support Center